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Abstract
Purpose In this double-blinded, randomised clinical trial,
the aim was to compare the analgesic effects of low doses
of intra-articular Bupivacaine and Ropivacaine against
placebo after knee arthroscopy performed under general
anaesthesia.
Methods A total of 282 patients were randomised to
10 cc NaCl 0.9%, 10 cc Bupivacaine 0.5% or 10 cc Rop-
ivacaine 0.75%. Patients received the assigned therapy by
intra-articular injection after closure of the portal. Pain and
satisfaction were measured at one, 4 h and 5–7 days after
arthroscopy with Numerical Rating Scale (NRS) -scores.
NSAID consumption was also recorded.
Results One-h NRS-scores at rest were higher in the NaCl
group compared with the Bupivacaine group (P\0.01),
1 h NRS-scores in ﬂexion were higher in the NaCl group
compared with the Bupivacaine (P\0.01) and Ropiva-
caine (P\0.01) groups. NRS-satisfaction at 4 h was
higher for the Bupivacaine group compared with the
NaCl group (P = 0.01). Differences in NRS-scores were
signiﬁcant but low in magnitude. NSAID consumption was
lower in the Bupivacaine group compared with the NaCl
group (P\0.01).
Conclusions The results of this randomised clinical trial
demonstrate improved analgesia after administration of
low doses of intra-articular Bupivacaine and Ropivacaine
after arthroscopy of the knee. Considering reports of
Bupivacaine and Ropivacaine being chondrotoxic agents
and the relatively small improvement on patient comfort
found in this trial, it is advised to use systemic anaesthetic
instead of intra-articular Bupivacaine or Ropivacaine for
pain relief after knee arthroscopy.
Level of evidence I.
Keywords Knee  Arthroscopy  Bupivacaine 
Ropivacaine  Intra-articular
Introduction
In 1931, Burman posted the knee as being a joint suitable
for arthroscopy [1]. Over time, more indications for
arthroscopy have been posted. Momentarily approximately
150.000-day care knee arthroscopies are performed a year
in The Netherlands.
Pain control in day care arthroscopy is essential for
patient comfort and early hospital discharge. Intra-articular
administration of single-dose local anaesthetic solutions is
used to provide better analgesia after knee arthroscopy and
reduce consumption and possible side effects of oral and
intravenous anaesthetic.
Although Bupivacaine and in some countries Ropiva-
caine are still commonly used in low doses as an intra-
articular anaesthetic after knee arthroscopy, evidence from
literature does not provide deﬁnite level I evidence to
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17, 19, 22].
If the effect of the intra-articular anaesthetic is proven
not clinically relevant this would be a deﬁnite argument to
stop the administration of these agents.
This study was designed to investigate the superiority of
single-low dose 10 cc Bupivacaine 0.5% and 10 cc Ropi-
vacaine 0.75% compared to physiologic saline after knee
arthroscopy performed under general anaesthesia. It was
hypothesised that intra-articular injection with Bupivacaine
or Ropivacaine was signiﬁcantly more effective than intra-
articular injection with saline.
Materials and methods
This study was a prospective, placebo controlled, ran-
domised double-blind clinical trial. The study protocol was
approved by the Medical Ethical Committee of the Uni-
versity of Utrecht, The Netherlands and was executed in
the Tergooi Hospitals, Hilversum, The Netherlands.
Inclusion criteria were the following: Patients sched-
uled for knee arthroscopy under general anaesthesia
without concomitant ligament or meniscal reconstruction,
cartilage transplantation or cartilage procedure, American
Society of Anaesthesiologists (ASA) classiﬁcation I and
II, and age over 18 years. Exclusion criteria were the
following: A history of adverse reactions to study medi-
cation, physical or mental handicaps not allowing the
regular rehabilitation or communication, and the use of
‘drugs’ or anaesthetic for prolonged episodes. From 2005
until 2010, a total of 282 patients were included, ran-
domised and analysed.
Patients were randomised into three groups: The Control
group was injected with 10 cc NaCl 0.9%; group Bupi was
injected with 10 cc Bupivacaine 0.5% (50 mg); and group
Ropi was injected with 10 cc Ropivacaine 0.75% (75 mg).
A total of 96 patients were allocated to the Control group.
Ninety-four patients were allocated to group Bupi, and 92
patients were allocated to group Ropi. All patients received
the allocated treatment. One patient in group Bupi was
excluded from analysis because the arthroscopy was per-
formed while this patient had total knee prosthesis in situ.
A total of 96 patients were analysed in the Control group,
90 patients in group Bupi and 90 patients in group Ropi
(Fig. 1).
In the outpatient clinic, a nurse handed out patient-
information when the patient got scheduled for surgery.
Written informed consent was obtained on the day of
surgery, after the patients were enabled to have read the
information. Randomisation was performed by a blinded
research assistant who randomly picked a closed opaque
envelope containing a treatment regimen. Patients were
randomised without stratiﬁcation. After inclusion, patients
received a study-diary in which study data were recorded.
Primary outcome measure was the 0–10 Numerical
Rating Scale (NRS) for pain at rest and in ﬂexion at
5–7 days after arthroscopy. The 0–10 NRS is an 11-point
scale with at the end points the extremes 0 (no pain) and 10
(worst pain). Patients were instructed to circle the numer-
ical value that best represented their pain level at that
moment. This scale is commonly used in clinical ortho-
paedic practice and is a reliable and valid outcome measure
for pain, with test–retest reliability coefﬁcients (ICC)
ranging from 0.77 to 0.94 [11].
Secondary outcomes were NRS for pain at rest and in
ﬂexion 1 and 4 h after arthroscopy, NRS for satisfaction,
and consumption of analgesics.
Assessments were performed preoperative, 1 h postop-
erative, 4 h postoperative and 5–7 days after surgery.
Before ﬁrst NRS-scores were obtained, patients were
informed how to use NRS-scores. NRS for satisfaction was
scored by having the patient rate their satisfaction with 0
being completely dissatisﬁed and 10 being completely
satisﬁed. All data were collected by a blinded research
assistant.
The arthroscopic procedures were performed by a group
of 4 orthopaedic surgeons and a changing number of res-
idents. Surgery was performed using a standard 2-portal
arthroscopy technique. The leg to be treated was positioned
in a leg clamp, and a tourniquet was inﬂated tot 350 mm
Hg. After surgery, a standard size bandage was applied.
All patients received standardised general anaesthesia
with propofol, sevoﬂurane and sufentanil during surgery.
The allocated sealed envelope was opened on the operating
room (OR) by OR-personnel. Ten cc of Bupivacaine 0.5%,
Ropivacaine 0.75% or NaCl 0.9% was than prepared by
OR-personnel in a syringe with a 40 mm needle. Allocated
treatment was injected by the surgeon through the portal
after closure of the portals with a suture for each portal, and
before the tourniquet was released and the patient woke up.
The surgeon was unblinded during injection of the study
drug for safety reasons, for example allergies or systemic
reactions.
After surgery, all patients were transferred to the
recovery room where the research-assistant collected 1 h
data. Before discharge, the 4 h data were collected.
Patients were given rescue medication at their own wish.
First rescue medication was oral or rectal NSAID, second
was a morﬁne analogist. All administered medication was
recorded in the patient’s diary.
Statistical analysis
Sample size calculation for this study was based on NRS
for pain. A clinically relevant difference between the
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123treatment groups was deﬁned as 1 point. With an assumed
standard deviation of 2 points and an a level of 0.05, 86
patients in each group were required to obtain a power of
90%. In order to incorporate an expected dropout rate of
10%, a total of 282 patients were required.
Analysis was performed with PASW 18.0 software
(IBM Company, Illinois, Chicago) and was based on the
intention-to-treat principle. Normality of the data was
checked by use of the Kolmogorov–Smirnov tests. Anal-
ysis of variance (ANOVA) tests was performed for the
comparison of age. Kruskall–Wallis (KW) tests were used
to compare other continuous data (with skewed distribu-
tions), such as surgery time and NRS-scores for pain and
satisfaction. When KW tests showed signiﬁcant differences
between the intervention groups, post hoc pairwise com-
parisons were performed by use of Mann–Whitney U tests
with adjustment of the signiﬁcance level for multiple
testing (Bonferroni). Categorical variables were analysed
with a Chi-square test or Fisher exact test. A P value\0.05
was considered as statistically signiﬁcant.
Results
Randomisation revealed three comparable cohorts, mean
age of the study population was 50.1 years (SD 14.6), and
male/female ratio was 135 (48%):147 (52%) (Table 1), and
median duration of surgery was 17 min (range 4–55).
Duration of surgery did signiﬁcantly differ between
residents and staff members performing the surgery
(P\0.01). Median duration of surgery by a staff member
was 13 min (range 4–37) and for a resident 18 min (range
7–55).
At 1 h postoperative, signiﬁcant differences between the
treatment groups were observed for pain at rest and ﬂexion
(P = 0.01 and P\0.01, respectively) and 4 h postopera-
tive for satisfaction (P = 0.02). (Figs. 2, 3)
Post hoc analysis with Bonferroni correction (signiﬁ-
cance level was adjusted to 0.017) for NRS at rest at 1 h
postoperative showed a signiﬁcant difference between the
Control and the Bupi group (P\0.01) and not between the
Control and Ropi group or Ropi and Bupi group. NRS at
ﬂexion 1 h postoperative showed signiﬁcant differences
between the Control and Bupi group as well as the Control
and Ropi group (P\0.01 and P\0.01, respectively)
(Fig. 3). Satisfaction at 4 h postoperative was only signif-
icantly different between the Control and Bupi group
(P = 0.01) (Fig. 4).
One h postoperative, NSAID consumption was reported
by 64 (67%) patients in the Control group, 42 (47%)
patients in the Bupi group and 38 (42%) patients in the
Ropi group. Signiﬁcantly, more patients in the Control
group used NSAID’s compared with the Bupi group
(P\0.01). No signiﬁcant differences were found com-
paring the Control group to the Ropi group or the Ropi
group to the Bupi group. At 4 h postoperative, no signiﬁ-
cant differences in escape medication were observed. No
adverse reactions were noted in all study groups.
Randomised: 
N= 282 
￿ Allocated to  
NaCL 0.9%:  
￿ N= 96 
￿ All patients 
received treatment 
￿ Allocated to 
Bupivacaine 0.5%: 
￿ N= 94 
￿ All patients received 
treatment 
￿ Allocated to 
Ropivacaine 0.75%: 
￿ N= 92 
￿ All patients received 
treatment 
￿ 0 lost to follow up 
￿ 0 discontinued 
intervention 
￿ 3 lost to follow up 
￿ 0 discontinued 
intervention 
￿ 2 lost to follow up 
￿ 0 discontinued 
intervention 
￿ 0 excluded from 
analysis 
￿ 96 analyzed 
￿ 1 excluded from 
analysis 
￿ 90 analyzed 
￿ 0 excluded from 
analysis 
￿ 90 analyzed 
Fig. 1 Flow diagram of the
study
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The most important ﬁnding of this study is that both intra-
articular 10 cc Bupivacaine 0.5% and 10 cc Ropivacaine
0.75% reduce pain in the ﬁrst postoperative period after
arthroscopy of the knee. Ropivacaine was less effective
than Bupivacaine for pain at rest at 1 h postoperative,
although NSAID consumption was not different between
Bupivacaine and Ropivacaine groups.
Though signiﬁcant, the analgesic effects were relatively
small and lasted for a short period of time; 4 h after sur-
gery, no difference in pain scores could be recorded any-
more between the groups. Patient satisfaction, however, did
differ 4 h after surgery. This can be the result of better
analgesia the hours before this measurement, which is
supported by the lower NRS-scores at 1 h postoperative.
The small and relatively short lasting effects as well as the,
Table 1 Baseline
characteristics and surgical data
No statistical differences were
observed between the treatment
groups
NaCl 0.9%
(n = 96)
Bupivacaine
0.5% (n = 94)
Ropivacaine
0.75% (n = 92)
All
(n = 282)
Mean age, years (SD) 50.1 (16.3) 50.2 (12.8) 49.6 (14.8) 50.1 (14.6)
Male (%) 40 (42%) 45 (48%) 50 (54%) 135 (48%)
Female (%) 56 (58%) 49 (52%) 42 (46%) 147 (52%)
Med meniscus lesion (%) 43 (45%) 45 (48%) 47 (51%) 135 (48%)
Lat meniscus lesion (%) 8 (8%) 11 (12%) 8 (9%) 27 (10%)
ACL rupture (%) 7 (7%) 3 (3%) 6 (6%) 16 (6%)
Degenerative changes (%) 28 (29%) 18 (19%) 15 (16%) 61 (22%)
Other diagnosis (%) (e.g. loose
bodies, plica synovialis)
10 (11%) 17 (18%) 16 (18%) 43 (15%)
Median NRS rest (range) 1 (0–10) 2 (0–9) 1 (0–8) 1 (0–10)
Median NRS ﬂexion (range) 5 (0–10) 4.5 (0–10) 5 (0–10) 5 (0–10)
Surgery by resident (%) 68 (71%) 59 (63%) 65 (71%) 192 (68%)
Surgery by staff (%) 28 (29%) 35 (37%) 27 (29%) 90 (32%)
Duration of surgery, min (range) 16 (4–36) 17 (8–40) 17 (4–55) 17 (4–55)
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*
Fig. 2 Median NRS (with interquartile ranges) for pain at rest.
*P\0.01
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Fig. 3 Median NRS (with interquartile ranges) for pain during
ﬂexion. *P\0.01
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*
Fig. 4 Median NRS (with interquartile range) for satisfaction.
*P = 0.01
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123though being signiﬁcant at 1 h postoperative at rest, small
differences between Bupivacaine and Ropivacaine can also
be the cause of the nonsigniﬁcant difference in NSAID
consumption between Bupivacaine and Ropivacaine
groups.
In 1999, Moiniche et al. [15] performed a review on
intra-articular Bupivacaine after knee arthroscopy. This
study could only provide weak evidence for a beneﬁcial
effect of Bupivacaine, especially in lower, 50 mg doses.
Reduction in pain scores was short in duration, and a dose-
dependent relationship for effectiveness could not be pro-
ven. Calmet et al. [2], using 10 cc Bupivacaine 0.25% in
patients with arthroscopic partial meniscectomies, proved
Bupivacaine to have a longer analgesic effect compared to
saline in a small group of patients. Dal et al. [8] showed
20 cc Bupivacaine 0.5% to be more effective for 24 h in a
study comparing Bupivacaine to saline in even smaller
groups of 15 patients scheduled for arthroscopy. Both these
studies, however, lacked a power analysis. More recent
work by Marret et al. [13] could not prove 30 cc Bupiva-
caine 0.5% to be more effective compared to saline in a,
however, power analysis based, small sample sized ran-
domised trial. However, 30 cc Ropivacaine 0.75% was
proven to be more effective compared with 30 cc saline or
30 cc Bupivacaine 0.5% with the effect lasting between 2
and 6 h for pain at ﬂexion. These results are conﬁrmed by
results of Convery et al. [6] demonstrating 20 cc Ropiva-
caine 0.75% to be superior to 20 cc Bupivacaine 0.5% in a
nonplacebo-controlled trial. An also nonplacebo-controlled
study performed under local anaesthesia could not prove
30 cc Ropivacaine 0.5% to be more effective compared
with 30 cc Bupivacaine 0.5% [17].
Francesci et al. [9] proved 20 cc Ropivacaine 0.375% to
be superior to 20 cc saline as placebo for the ﬁrst 4 h, but
these results cannot be conﬁrmed by Santanen et al. in a
study performed under spinal anaesthesia using 20 cc
Ropivacaine 0.5% compared to placebo.
These previous results are in concordance with the sig-
niﬁcant, but relatively small and short-lasting effects of
10 cc Bupivacaine 0.5% and 10 cc Ropivacaine 0.75%
compared to saline found in this study. However, we could
not conﬁrm 10 cc Ropivacaine 0.75% to be superior to
10 cc Bupivacaine 0.5%.
Both Bupivacaine and Ropivacaine have proven to have
systemic concentrations below known toxic levels after
intra-articular injection of the knee and should, therefore,
be safe to use intra-articularly [12, 14, 17, 22].
Despite this, recent reports have shown chondrotoxic
effects of both Bupivacaine 0.5 and 0.25% in vitro as well
as in vivo [3–5]. Ropivacaine 0.5% also has chondrotoxic
effects, although to a less extend than Bupivacaine 0.5%
when tested in vitro [10, 18]. Both substances appear to
display a dose dependent effect, making a low dose intra-
articular injection strategy possibly the least harmful [10].
Though the evidence for chondrotoxicity is quite strong,
the incidence of chondrolysis following intra-articular
administration of Bupivacaine in clinical practice seems to
be low or possibly underreported. Most reported cases have
been after shoulder arthroscopy in combination with con-
tinuous infusion of Bupivacaine [20].
A possible limitation of this study design is our ran-
domisation system. Although no differences in demo-
graphics were recorded, a computer-block-randomisation
system would have been safer. Another possible limitation
is the inclusion of a relative large amount of patients with
degenerative changes as this possibly results in higher
postoperative pain-scores.
The quite low NRS-scores found in this study are the
result of the administration of systemic analgesics. Other
methods of improving patient comfort should be explored
to reduce potential side effects of these systemic analge-
sics. Locoregional anaesthesia techniques are explored, but
the need for a nerve stimulator, the time needed to apply
the nerve block and possibility of a failure of the block
(10%) make this technique less appropriate for day care
surgery. However, when compared to spinal anaesthesia,
locoregional anaesthesia provides better postoperative
analgesia [7, 16].
Portal anaesthesia combined with general anaesthesia is
another possible alternative. Townshend et al. [21] have
shown portal anaesthesia with 20 cc Bupivacaine 0.5%
(100 mg) to be as effective as intra-articular anaesthesia
with 20 cc Bupivacaine 0.5%. Further research should
focus on this simple, low cost and probably safe technique
to improve patient comfort.
Considering the possible side effects and the, though
signiﬁcant, relatively small and short lasting improvement
in already quite low NRS-scores, the administration of
intra-articular Bupivacaine or Ropivacaine should be dis-
couraged in favour of systemic anaesthetic until alternative
techniques are available.
Conclusion
The analgesic effects of intra-articular Bupivacaine and
Ropivacaine after knee arthroscopy are clinically signiﬁ-
cant when compared to placebo. However, considering the
improvement in patient comfort on one side, but the short
duration and small amount of this improvement and the
risk of chondrotoxicity on the other side, the administration
of intra-articular analgesia with Bupivacaine or Ropiva-
caine cannot be recommended.
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